About JLS Fund
JLS Fund is a venture capital firm founded in 2019. It is primarily based out of New York City, United States. As of Jan 2025, JLS Fund has invested in 28 companies. It primarily invests in Seed round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to HealthTech and Consumer. Most recently it participated in the $***** Series A round of Immunis Overall, JLS Fund portfolio has seen 3 IPOs and 2 acquisitions including key companies like MindMed, Cybin and AtaiBeckley. A lot of funds co-invest with JLS Fund, with names like Palo Santo sharing a substantial percentage of its portfolio. JLS Fund has team of 15 people including 3 partners.Key Metrics
Team Members
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Seed, Series A & 1 more
Portfolio Acquisitions
JLS Fund's List of Top Investments
JLS Fund has a portfolio of 28 companies. Their most notable investments are in Fluence and Fluence.Their portfolio spans across United States and Canada. They have invested in Life Sciences, HealthTech, Consumer and 10 other sectors, across stages such as Seed, Series A and 1 more. Here is the list of top investments by JLS Fund:
1. TRIPP
TRIPP is a wellness technology company that is developing mood-altering virtual reality experiences. The experience combines audio & visual elements, gameplay mechanics, and meditation taking the users on a journey that can stimulate multiple feelings and moods. The company claims that the experiences can deliver a more focused brain stimulation that could improve a person’s well-being and mental health. Partners include Facebook, Google, Unity, STEAM, HTC, and Oculus.
Key facts about TRIPP
- Founded Year: 2016
- Location: Los Angeles (United States)
- Stage: Series A
- Total Funding till date: $26.3M
- Employee Count: 26 as on Aug 31, 2026
- Investors: Qualcomm Ventures, Seven Hound Ventures and 31 Others
- Latest Funding Round: Series A, Jun 01, 2022, $*****
- Highlight: Editors' Pick
2. MindMed
Developer of psychedelic-based therapies for brain health disorders. It develops product candidates to treat conditions such as generalized anxiety disorder, major depressive disorder, and autism spectrum disorder. The company utilizes rigorous scientific methods and focuses on addressing unmet patient needs in these therapeutic areas. Research and development efforts encompass diverse therapeutic areas and mechanisms of action.
Key facts about MindMed
- Founded Year: 2019
- Location: New York City (United States)
- Stage: Public
- Employee Count: 30 as on May 31, 2026
- Investors: TR Ventures, K2 HealthVentures and 9 Others
- Latest Funding Round: Post IPO, Mar 11, 2024, $*****
- Highlight: Public
3. Gilgamesh
Developer of drugs for neuropsychiatric conditions. The company has an AI-powered discovery and translational platform to develop novel psychotropic drugs for the treatment of neuropsychiatric conditions including depression, anxiety, substance use, and stress-related disorders. Products include GM-1020 and GM-2505 an oral NMDAR Antagonist.
Key facts about Gilgamesh
- Founded Year: 2019
- Location: New York City (United States)
- Valuation: $*****
- Stage: Series B
- Total Funding till date: $152M
- Investors: Seven Hound Ventures, Satori Capital and 18 Others
- Latest Funding Round: Series B, Mar 27, 2026, $*****
- Highlight: Editors' Pick
AiVita Biomedical is a developer of dendritic cell immunotherapy for cancer and markets stem cells based facial serum for skincare. It has a Phase II-ready patient-specific dendritic cell immunotherapy, currently being investigated for the treatment of ovarian cancer. The treatment of autologous dendritic cells loaded with autologous irradiated tumour cells, directs the patient’s own immune system to seek out and destroy the very cells responsible for the growth and spread of the disease. The company is also developing an immune monitoring technology to be used in conjunction with its immunotherapeutic approach.
Key facts about AiVita Biomedical
- Founded Year: 2016
- Location: Irvine (United States)
- Stage: Series B
- Total Funding till date: $46M
- Employee Count: 24 as on Aug 31, 2026
- Investors: CIRM, Ci:z Investment and 6 Others
- Latest Funding Round: Series B, Dec 29, 2020, $*****
- Highlight: Editors' Pick
5. Cybin
Provider of psychedelic therapeutics for psychiatric disorders. The product pipeline includes CYB003 a deuterated psilocin for the adjunctive treatment of major depressive disorderCYB004 deuterated dimethyltryptamine compound targeting generalized anxiety disorder and CYB005 aphenethylamine derivative treating neuroinflammation.
Key facts about Cybin
- Founded Year: 2002
- Location: Toronto (Canada)
- Stage: Public
- Employee Count: 108 as on Sep 30, 2026
- Investors: Deep Track Capital, LifeSci Venture Partners and 10 Others
- Latest Funding Round: Post IPO, Jun 30, 2025, $*****
- Highlight: Public
JLS Fund's Year-on-Year Investment Trends
JLS Fund has invested in 28 companies over the last 5 years, with an average of 1 new investment annually in the last 5 years. In 2025, it made 1 investment. Its most recent first time investment was in Immunis and most recent follow-on round was in Gilgamesh.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 0 | 0 | 0 |
2025 | 1 | 0 | 1 |
2024 | 0 | 0 | 0 |
2023 | 0 | 0 | 0 |
2022 | 1 | 2 | 3 |
2021 | 4 | 0 | 4 |
JLS Fund's Investments by Stage
JLS Fund has made 3 investments in Seed stage with an average round size of $2.7M, 2 investments in Series A stage with an average round size of $26M and 1 investment in Post IPO stage.Stage of entry | No. of Investments |
|---|---|
Seed | 3 |
Series A | 2 |
Post IPO | 1 |
Note: We have considered here, only first round of investments
JLS Fund's Investments by Sector
JLS Fund has a diverse portfolio, with companies operating in the Consumer, Life Sciences, Education and HealthTech. Notably, it has invested in 23 Tech companies, 19 Enterprise (B2B) companies, 8 Software companies and at least 7 companies focusing on Consumer (B2C).Sector | No. of Investments |
|---|---|
Consumer | 4 |
Life Sciences | 4 |
Education | 1 |
HealthTech | 1 |
Note: We have considered here, only first round of investments
JLS Fund's Investments by Geography
JLS Fund has made most investments in United States (5), followed by Canada where it has made 1 investment.Country | No. of Investments |
|---|---|
United States | 5 |
Canada | 1 |
Note: We have considered here, only first round of investments
JLS Fund's recent investments
JLS Fund has not made any investment in 2026 so far.Here are the most recent investments by JLS Fund:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Jan 11, 2025 | United States | Series A | 2638 | [+3] | |
Dec 15, 2022 | United States | Series B | 6530 | [+6] | |
Apr 07, 2022 | Canada | Seed | 5174 | [+8] | |
Feb 15, 2022 | United States | Seed | 6355 | [+9] | |
Nov 04, 2021 | United States | Seed | 7560 | [+1] |
IPOs and Publicly Listed companies in JLS Fund's Portfolio
3 of JLS Fund's portfolio companies have become public. MindMed got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Apr 2021 at marketcap of undefined and Cybin got listed on the American Stock Exchange (NYSEAMERICAN).Here are JLS Fund's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Apr 27, 2021 | - | - | 6048 | |
Sep 13, 2019 | - | - | 7324 | |
Dec 13, 2011 | Mar 31, 2021 | Post IPO | 3972 |
Acquired companies in JLS Fund's Portfolio
2 companies from JLS Fund's portfolio have been acquired. The most recent acquisition was AtaiBeckley in Jul 2026 by Lilly for $*****.Here are JLS Fund's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Jul 16, 2026 | - | - | 9533 | |
May 20, 2020 | - | - | 6615 |
Team profile of JLS Fund
JLS Fund has a team of 15 members including 3 Partners and 1 Principal located in United States and Canada. JLS Fund's team does not sit on the board of any company as of now.Here is a list of top team members in JLS Fund:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | Carmel Valley | - | ||
Partner | Baltimore | - | ||
Partner | Northbrook | - | - | |
Principal | Toronto | - |
Co-investors of JLS Fund
Over the past 5 years, 40 investors have co-invested in JLS Fund's portfolio companies. This includes funds and angels.
- Invested before JLS Fund: Y Combinator, Remiges Ventures and 2 others have invested in rounds before JLS Fund. There is 1 company where Y Combinator has invested before JLS Fund and 1 company where Remiges Ventures has invested before JLS Fund.
- Top Co-investors of JLS Fund: 24 investors entered a company along with JLS Fund. These include investors like Palo Santo (2 companies).
- Invested after JLS Fund: A total of 12 investors have invested in JLS Fund's portfolio after their investments. Top Investors include HHS (2 companies), Alumni Ventures (1 company) and Negev Capital (1 company).
Recent News related to JLS Fund
•
Immunis Closes $25 Million Series A-1 Financing RoundYahoo•Jan 11, 2025•Immunis, Remiges Ventures, Continuum Health Ventures, Bold Capital Partners and 2 others
•
Gilgamesh raises funds to advance treatments for mental healthPharmaceutical Business Review•Dec 16, 2022•Prime Movers Lab, Gilgamesh, Alumni Ventures, Palo Santo and 5 others
•
Homecoming Closes $4 Million Seed Funding Round To Scale Psychedelic Therapy Companion ToolsPRWeb•Apr 06, 2022•Homecoming, JLS Fund, Lionheart Ventures, Bridge Builders Collaborative and 3 others
•
Fluence Raises $3M in Seed FundingFinSMEs•Feb 27, 2022•Fluence, JLS Fund, Neo Kuma Ventures, LearnStart and 3 others
•
Psilera Raises $2.5M in Seed FundingFinSMEs•Jul 02, 2021•Psilera, Iter Investments, Baird, JLS Fund and 1 other
•
Psychedelic alternative realties company scores $11M in Series A fundingMobiHealthNews•Jun 25, 2021•TRIPP, Vine Ventures, Mayfield, Integrated Ventures and 21 others
•
New York-based biotech startup Gilgamesh Pharmaceuticals raises $27M Series A to develop psychedelic medicines to treat mental illnessTechStartups.com•May 06, 2021•Gilgamesh, Prime Movers Lab, Noetic Psychedelic Fund, Gron Ventures and 3 others
•
